Regeneron COVID-19 treatment enters final stage trials | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Sunday
December 03, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
SUNDAY, DECEMBER 03, 2023
Regeneron COVID-19 treatment enters final stage trials

Coronavirus chronicle

BSS/AFP
07 July, 2020, 12:45 pm
Last modified: 07 July, 2020, 12:48 pm

Related News

  • Coronavirus origins still a mystery 3 years into pandemic
  • Covid remains a public health emergency, says WHO
  • Potential China wave is 'wild card' for ending Covid emergency: WHO advisors
  • WHO chief hopes Covid will no longer be emergency next year
  • The Prof Writes: Covid-19 - The one that got away from us

Regeneron COVID-19 treatment enters final stage trials

This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US

BSS/AFP
07 July, 2020, 12:45 pm
Last modified: 07 July, 2020, 12:48 pm
Regeneron COVID-19 treatment enters final stage trials

The pharmaceutical firm Regeneron on Monday announced it was entering the late stages of its human clinical trials investigating a drug to both treat and prevent COVID-19.

The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus' "spike protein" which it uses to invade human cells.

The company is moving to the final Phase 3 stage of a trial to determine if its drug can prevent infection among people recently exposed to the virus — for example through a person in their household.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US.

"We are pleased to collaborate with NIAID to study REGN-COV2 in our quest to further prevent the spread of the virus with an antiviral antibody cocktail that could be available much sooner than a vaccine," said Regeneron President George Yancopoulos.

At the same time, Regeneron announced it was moving to the final stages of a trial to determine the drug cocktail's ability to treat both hospitalized and non-hospitalized COVID-19 patients.

This will involve around 1,850 hospitalized and 1,050 non-hospitalized patients in the US, Brazil, Mexico and Chile, with preliminary data expected later this summer.

Regeneron scientists evaluated thousands of antibodies harvested from genetically modified mice and from humans, identifying the two they found to be most potent against the SARS-CoV-2 virus, while not competing against each other.

The company uses a multi-antibody strategy to decrease the chances that the virus will mutate in order to evade the blocking action of a single antibody, an approach it detailed in a recent study in Science.

Last year, a triple antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.

Top News

Regeneron / Coronavirus

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Poultry farmers face crisis as rising feed prices outpace production cost
    Poultry farmers face crisis as rising feed prices outpace production cost
  • File photo of Awami League General Secretary and Road Transport and Bridges Minister Obaidul Quader
    No AL member running as independent candidate will be expelled: Quader
  • Paperfly founders set to buy out foreign investor's entire stake
    Paperfly founders set to buy out foreign investor's entire stake

MOST VIEWED

  • Representative image
    5.5 magnitude earthquake jolts Dhaka, parts of country
  • Cox's Bazar Express started its first journey from Cox's Bazar to Dhaka at 12:40pm on Friday (1 December). Photo: Nupa Alam
    Man crushed by Cox's Bazar Express on debut journey
  • Representative image
    BCS admin cadres' organisation forays into luxury hotel business
  • Will Bangladeshi garment exporters be able to meet EU's upcoming standards?
    Will Bangladeshi garment exporters be able to meet EU's upcoming standards?
  • Coxs Bazar express started for Dhakat at 12:40pm on 1 December. Photo: TBS
    Train to the sea: Dhaka-Cox's Bazar rail service begins
  • Collage of the Android Earthquake Alerts System screenshots posted on the social media on Saturday, 2 December 2023
    Here’s how your Android phone alerts you of an earthquake

Related News

  • Coronavirus origins still a mystery 3 years into pandemic
  • Covid remains a public health emergency, says WHO
  • Potential China wave is 'wild card' for ending Covid emergency: WHO advisors
  • WHO chief hopes Covid will no longer be emergency next year
  • The Prof Writes: Covid-19 - The one that got away from us

Features

Jannatul Ferdous Ivy has written 11 books so far with the latest, a series of poems, being published this year. Photo: Noor-A-Alam

Jannatul Ferdous Ivy: Overcoming tragedy, excelling in life

6h | Panorama
According to public health experts, our healthcare is not well-equipped and we do not have the required number of doctors in proportion to our population. Photo: Saqlain Rizve

How inclusive is our healthcare system?

6h | Panorama
Photo: Rony Rezaul

Stand out in Style: Explore Apex's Wedding Season Collection

23h | Mode
TBS Illustration

The origins of electoral symbols

1d | Panorama

More Videos from TBS

Israel's war on Palestine is a boon for the United States

Israel's war on Palestine is a boon for the United States

2h | TBS World
Nomination for independent candidates hits the history!

Nomination for independent candidates hits the history!

15h | TBS Stories
Tiger bowlers who have taken 10 wickets in a Test match are spinners

Tiger bowlers who have taken 10 wickets in a Test match are spinners

16h | TBS SPORTS
Annual production of ducks is more than 6.5 crores

Annual production of ducks is more than 6.5 crores

18h | TBS Economy
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]